Nurix Therapeutics Inc (NASDAQ: NRIX) is 163.95% higher on its value in year-to-date trading and has touched a low of $4.96 and a high of $27.60 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NRIX stock was last observed hovering at around $27.00 in the last trading session, with the day’s gains setting it 0.24%.
Currently trading at $27.24, the stock is 7.67% and 12.08% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.98 million and changing 0.89% at the moment leaves the stock 50.37% off its SMA200. NRIX registered 352.49% gain for a year compared to 6-month gain of 95.27%. The firm has a 50-day simple moving average (SMA 50) of $24.2602 and a 200-day simple moving average (SMA200) of $18.018475.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 23.87% loss in the last 1 month and extending the period to 3 months gives it a 30.84%, and is 10.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.17% over the week and 5.71% over the month.
Nurix Therapeutics Inc (NRIX) has around 284 employees, a market worth around $1.93B and $56.42M in sales. Profit margin for the company is -313.65%. Distance from 52-week low is 449.19% and -1.30% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.53%).
The EPS is expected to shrink by -5.33% this year
253.0 institutions hold shares in Nurix Therapeutics Inc (NRIX), with institutional investors hold 96.85% of the company’s shares. The shares outstanding are 70.84M, and float is at 69.64M with Short Float at 13.27%. Institutions hold 95.44% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.82 million shares valued at $142.33 million. The investor’s holdings represent 12.4218 of the NRIX Shares outstanding. As of 2024-06-30, the second largest holder is REDMILE GROUP, LLC with 4.42 million shares valued at $92.32 million to account for 8.0571 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 3.99 million shares representing 7.27 and valued at over $83.3 million, while BAKER BROS. ADVISORS LP holds 7.0708 of the shares totaling 3.88 million with a market value of $81.02 million.
Nurix Therapeutics Inc (NRIX) Insider Activity
The most recent transaction is an insider sale by Ring Christine, the company’s Chief Legal Officer. SEC filings show that Ring Christine sold 3,290 shares of the company’s common stock on Nov 04 ’24 at a price of $25.00 per share for a total of $82250.0. Following the sale, the insider now owns 28084.0 shares.
Still, SEC filings show that on Nov 01 ’24, Ring Christine (Chief Legal Officer) disposed off 5,760 shares at an average price of $24.28 for $0.14 million. The insider now directly holds 28,084 shares of Nurix Therapeutics Inc (NRIX).
